Cat. No. 1104
Chemical Name: 1-[2-Chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-β-D-ribofuranuronamide
Biological ActivityHigh affinity and extremely selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. Exhibits high selectivity over the Na+-independent adenosine transporter.
Licensing InformationSold with the permission of the NIH, US Patent 08/091,109
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Kim et al (1994) 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J.Med.Chem. 37 3614. PMID: 7932588.
Schaick et al (1996) Hemodynamic effects of histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur.J.Pharmacol. 308 311. PMID: 8858305.
Jacobson (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. TiPS 19 184. PMID: 9652191.
If you know of a relevant citation for this product please let us know.
Keywords: 2-Cl-IB-MECA, supplier, selective, A3, agonists, Receptors, adenosines, 2ClIBMECA
Find multiple products by catalog number
New Products in this Area
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.